A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

NCT05814848 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Lymphoma

Interventions

DRUG: Relmacabtagene Autoleucel Injection

Sponsor

Changhai Hospital